•Diverse experiences at emerging biotechnology companies with a recent focus on liver disease and genetic medicines 🧬
•Raised over $1.7 billion and executed multiple licensing/M&A deals (including $877MM sale of Nightstar to Biogen)
•Well-respected by investors, investment bankers, and research analysts (ranked #2 on Institutional Investor All-America Executive Team)
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.